Attached files
| file | filename |
|---|---|
| 8-K - PDL BIOPHARMA, INC. | v206033_8k.htm |
|
Contacts:
|
||
|
Cris
Larson
|
Jennifer
Williams
|
|
|
PDL
BioPharma, Inc.
|
Cook
Williams Communications, Inc.
|
|
|
775-832-8505
|
360-668-3701
|
|
|
cris.larson@pdl.com
|
|
jennifer@cwcomm.org
|
U.S.
Patent and Trademark Office Terminates Interference Proceeding
in
Favor of PDL BioPharma, Inc.
INCLINE
VILLAGE, NV, December 20, 2010 — PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today
announced that on December 15, 2010, the U.S. Patent and Trademark Office (the
PTO) terminated its interference proceeding between certain claims of the
Company’s Queen et al., U.S. Patent No. 5,585,089, (the ‘089 Patent) and certain
pending claims of Adair et al., U.S. Application No. 08/846,658, (the ‘658
Application) in favor of the Company’s ‘089 Patent. The PTO held that
the involved claims in the ‘658 Application, are not patentable. UCB Pharma
S.A. is the assignee of the ‘658 Application.
About
PDL BioPharma
PDL
pioneered the humanization of monoclonal antibodies and, by doing so, enabled
the discovery of a new generation of targeted treatments for cancer and
immunologic diseases. PDL is focused on maximizing the value of its antibody
humanization patents and related assets. The Company receives royalties on sales
of a number of humanized antibody products marketed by leading pharmaceutical
and biotechnology companies today based on patents which expire in late 2014.
For more information, please visit www.pdl.com.
NOTE: PDL
BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma,
Inc.
# #
#